• In early August 2026, Health Canada authorized Moderna to begin a Phase I clinical trial of its Bundibugyo virus (Ebola) mRNA vaccine candidate, making Canada the second country after the U.K. to clear first-in-human testing focused on safety, dosing and immune response.
• This early-stage authorization, in an area with no licensed Bundibugyo vaccine or treatment, underscores Moderna’s push to extend its mRNA platform beyond seasonal respiratory vaccines into high-need infectious diseases.
• We’ll now examine how this Bundibugyo Ebola trial progress shapes Moderna’s broader investment narrative around pipeline diversification and long-term growth.

The latest GPUs need a type of rare earth metal called Terbium and there are only 28 companies in the world exploring or producing it. Find the list for free.

Moderna Investment Narrative Recap

To own Moderna, you have to believe its mRNA platform can expand beyond COVID and seasonal flu into a broader, more durable portfolio, while losses remain manageable. The new Bundibugyo Ebola Phase I trial in Canada is an early, high-need proof point for that diversification, but it is not a near-term revenue driver. The key short term catalyst still sits with respiratory vaccine approvals, while the biggest risk remains revenue volatility as COVID and RSV demand evolve.

Among recent announcements, the reaffirmed 2026 revenue guidance of up to 10% growth and a roughly 50/50 U.S. and international mix matters most here. It shows management still expects the existing vaccine and partnership base to carry the financial story in the near term, while programs like the Ebola candidate support the longer term pipeline case rather than changing the current revenue or profitability outlook.

Yet while this Ebola trial sounds encouraging, investors should be aware that...

Moderna's narrative projects $3.7 billion revenue and $695.7 million earnings by 2029.

Uncover how Moderna's forecasts yield a $44.25 fair value, a 25% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling revenue of about US$7.9 billion and a return to positive earnings by 2029, so this kind of early stage pipeline news could either strengthen that bullish view or highlight how dependent it is on many things going right across infectious disease programs.

Explore 6 other fair value estimates on Moderna - why the stock might be worth as much as 12% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Moderna research is our analysis highlighting 1 key reward that could impact your investment decision.
• Our free Moderna research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Moderna's overall financial health at a glance.

Want Some Alternatives?

Our top stock finds are flying under the radar-for now. Get in early:

• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.